L-838417 manufacturers
- L-838417
-
-
2026-08-07
- CAS:286456-42-6
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1000kg
- L-838417
-
- $48.00
-
2026-07-27
- CAS:286456-42-6
- Purity: 99.95%
- Supply Ability: 10g
|
| | L-838417 Basic information |
| Product Name: | L-838417 | | Synonyms: | 7-(tert-Butyl)-3-(2,5-difluorophenyl)-6-((1-methyl-1H-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine;1,2,4-Triazolo[4,3-b]pyridazine,3-(2,5-difluorophenyl)-7-(1,1-dimethylethyl)-6-[(1-methyl-1H-1,2,4-triazol-5-yl)methoxy]-;L-838417 ;3-(2,5-Difluorophenyl)-7-(1,1-dimethylethyl)-6-[(1-methyl-1H-1,2,4,-triazol-5-yl)methoxy]-1,2,4-triazolo[4,3-b]pyridazine;5-({[7-tert-butyl-3-(2,5-difluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]oxy}methyl)-1-methyl-1,2,4-triazole;L-838417_x000b_;3-(2,5-Difluorophenyl)-7-(1,1-dimethylethyl)-6-[(1-methyl-1H-1,2,4,-triazol-5-yl)methoxy]-1,2,4-triazolo[4,3-β]pyridazine;3-(2,5-Difluorophenyl)-7-(1,1-dimethylethyl)-6-[(1-methyl-1H-1,2,4-triazol-5-yl)methoxy]-1,2,4-triazolo[4,3-b]pyridazine (ACI) | | CAS: | 286456-42-6 | | MF: | C19H19F2N7O | | MW: | 399.4 | | EINECS: | | | Product Categories: | Heterocycles;Intermediates & Fine Chemicals;Heterocyclic Compounds;Pharmaceuticals | | Mol File: | 286456-42-6.mol |  |
| | L-838417 Chemical Properties |
| Melting point | 196-198°C | | density | 1.40±0.1 g/cm3(Predicted) | | storage temp. | Store at +4°C | | solubility | DMSO: ≥20mg/mL | | pka | 2.13±0.10(Predicted) | | form | powder | | color | white to off-white |
| | L-838417 Usage And Synthesis |
| Chemical Properties | White to Off-White Solid | | Uses | A selective ligand for GABAA receptors | | Uses | L-838417 is an anxiolytic agent and a selective GABAA receptor partial agonist that selectively binds to α1, α2, α3 and α5 subunits (1,2). It also exhibits antinociceptive and anti-inflammatory properties. | | Biological Activity | Subtype-selective GABA A receptor partial agonist. Selectively binds to α 1, α 2, α 3 and α 5 subunits (K i values are 0.79, 0.67, 0.67 and 2.25 nM respectively) but displays no efficacy at α 1 ( α 1-sparing). Exhibits non-sedative anxiolytic, antinociceptive and anti-inflammatory activity in vivo . | | in vivo | L-838417 (1.0 mg/kg) produces anxiolytic effects in adult rat, as indexed by a transformation of social avoidance into preference and an increase in social investigation[2].
L-838417 (2.0 mg/kg) eliminates social avoidance, but has no anxiolytic effects on social investigation[2].
L-838417 (0.5 mg/kg) reverses the anxiogenic effects of prior stress regardless of age, but with doses ≥ 1 mg/kg decreases social investigation, an effect possibly due in part to locomotor-impairing effects of this compound[2].
| Animal Model: | Male and female adolescent and adult Sprague–Dawley rats[2]. | | Dosage: | 0, 0.5, 1.0, 2.0, or 4.0 mg/kg. | | Administration: | IP. | | Result: | Adolescents required a higher dose (2 mg/kg) to attenuate their social avoidance.
The lowest dose of 0.5 mg/kg was sufficient to reverse the anxiogenic effects of repeated restraint as reflected by a significant increase in the coefficient relative to vehicle-treated animals.
|
| | storage | Store at +4°C |
| | L-838417 Preparation Products And Raw materials |
|